Every material Form 8-K Teladoc Health, Inc. has filed with the SEC since August 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Teladoc Health reported third quarter 2026 revenue of $605.1 million, down 3% from a year earlier, while its net loss narrowed to $26.9 million, or $0.15 per share, from $49.5 million, or $0.28 per share. The company also issued full-year and fourth-quarter 2026 outlook ranges, which show revenue of $2,395 million to $2,441 million for the year and a net loss per share of ($0.95) to ($0.75).
Q3 2026 revenue was $605.1 million, down 3%; BetterHelp revenue fell 13% to $206.6 million while Integrated Care rose 2% to $398.5 million.
Q3 2026 adjusted EBITDA was $79.4 million, up 14% from $69.9 million in Q3 2025.
Q3 2026 net loss included $88.3 million of intangible amortization and $4.4 million of restructuring costs.
Full-year 2026 outlook: revenue $2,395 million to $2,441 million; adjusted EBITDA $277 million to $303 million; Q4 2026 revenue $569 million to $615 million.
Teladoc Health said its Chief Legal Officer and Secretary, Adam C. Vandervoort, will resign effective November 1, 2026, with the resignation made for good reason under his executive severance agreement. Jonathan Dorfman, the company's Senior Vice President, Securities & Corporate Law, will succeed him in both roles, which matters to shareholders as a senior legal leadership change with a defined handover period.
Adam C. Vandervoort notified the company of his resignation on September 24, 2026, effective November 1, 2026.
Vandervoort will provide advisory services, including transition support, until November 1, 2027, with no compensation for those services.
Jonathan Dorfman will become Chief Legal Officer and Secretary after Vandervoort's departure.
Teladoc Health hired Michael Grasher as its Chief Financial Officer effective August 31, 2026, filling a role that Chief Executive Officer Charles Divita, III had held on an interim basis. Mr. Grasher previously served as CFO of IFG Companies from February 2024 to September 2025 and held CFO roles at Fortegra Group and AMERISAFE, Inc. The filing sets out his base salary, sign-on bonus, equity award and severance terms.
Annual base salary of $550,000 and a one-time sign-on bonus of $500,000
New-hire equity award with an aggregate target value of approximately $3,000,000, expected to be issued September 1, 2026, split 50% restricted stock units and 50% performance stock units
Annual bonus target of 85% of base salary, beginning with respect to 2027
Severance if terminated without cause or resigning for good reason outside a change of control: 12 months of base salary; 18 months if within 12 months after a change of control
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Teladoc Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →